Pharmafile Logo
Pharmafocus logo
Advanced Search

Medical Communications

Showing 15 posts of 6408 posts found.

novartis_side_building

Novartis reshuffle begins under new CEO

March 13, 2018 Manufacturing and Production, Medical Communications Novartis, biotech, digital, drugs, pharma, pharmaceutical

It’s a common strategy that newly appointed CEOs will try to change the direction of the company via rejigging leadership …
News
shutterstock_79370437

Drug safety: EudraVigilance and an evolving system

March 12, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing drug safety, pharma, pharmacovigilance

The importance of drug safety is back in the news due to sodium valproate and Ben Hargreaves examines how the …
Feature
martin_shkreli_house_committee_on_oversight_and_government_reform_2016

Martin Shkreli sentenced to seven years in jail for securities fraud

March 12, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Martin Shkreli, pharma

Three years after he became “the most hated man in America” overnight for jacking up the price of life-saving HIV-related …
News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

March 9, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Biogen, Celgene, EMA, Gilead, HIV, Herceptin, Japan, NHS, Ontruzant, Sanofi, opioid crisis, opioids, pharma, real world data, top ten, zinbryta

After a particularly jarring bout of cold weather and snow, we may just have seen off the worst of winter …
News
gsk_boronia_australia

GSK loses £37m appeal over pay-to-delay tactics to block Seroxat competition

March 9, 2018 Medical Communications, Sales and Marketing GSK, Pay to delay, Seroxat, antidepressant, pay-to-delay, pharma

GlaxoSmithKline has suffered a sizeable blow after losing an appeal disputing that it had engaged in anti-competitive pay-to-delay tactics to …
News
convert-logo1

Convert secures €13.6m grant to develop targeted chemo for oxygen-deprived tumours

March 9, 2018 Medical Communications, Research and Development Belgium, Cancer, Convert pharma, chemotherapy, pharma

Belgium’s Convert Pharmaceuticals has secured a €13.6 million grant for initial development efforts on a new targeted chemotherapy drug which …
News
regeneron

Appeal could throw spanner in the works for Regeneron’s Irish expansion

March 9, 2018 Manufacturing and Production, Medical Communications Ireland, Regeneron, pharma

Regeneron is facing a single man-sized obstacle in plans to expand operations at its campus in Limerick, Ireland with a …
News
vbl-big

VBL Therapeutics’ shares plummet on Phase 3 glioblastoma failure

March 9, 2018 Medical Communications, Research and Development VBL, VBL Therapeutics, glioblastoma, pharma, trial failure

Israeli drug development firm VBL Therapeutics has been left reeling after it announced that its lead oncology product ofranergene obadenovec, …
News
opioid_therapy_credit_-_us_air_force_valerie_monroy

Opioids are no more effective than common painkillers, study reveals

March 8, 2018 Medical Communications, Research and Development US, opioid crisis, opioids, pharma

A team of researchers at the Minneapolis Veterans Affairs Health Care System has found that, for all their risks, opioids …
News
martin_shkreli_2016

Martin Shkreli ordered to forfeit $7.36m ahead of fraud sentencing

March 6, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Martin Shkreli, pharma

Reviled pharma bro Martin Shkreli is experiencing another heavy dose of karma after a US judge ordered him to forfeit …
News
shutterstock_141105490

Uncovering trends in the future of real world data

March 5, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, AstraZeneca, feature, pharma, real world data, real world evidence

A new report has canvassed the intentions of industry players in the use of real world data and evidence over …
Feature
top_ten

Top Ten most popular articles on Pharmafile.com this week

March 2, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Alzheimer's, AstraZeneca, Botox, Celgene, EMA, FDA, Merck, Mylan, Pfizer, Roche, Takeda, ipsen, vaccines

We’re already into March and, trying to put a bad start to the year behind them on Alzheimer’s research, the …
News
endo-international

Endo granted injunction to block blood pressure competitor

March 2, 2018 Medical Communications, Sales and Marketing Endo, QuVa, Vasostrict, blood pressure, pharma, vasopressin

Generics and speciality pharma firm Endo International has revealed that it has been granted a preliminary injunction to block  competitor …
News
diabetes-2424105_960_720

Study identifies five kinds of diabetes, potentially changing treatment

March 2, 2018 Medical Communications, Research and Development biotech, diabetes, drugs, pharma, pharmaceutical

A decade-long study has unearthed findings that could entirely change how people living with diabetes are treated, after the classic …
News
shutterstock_92671375

Artificial Cell Technologies CFO accused of stealing nearly $1m in company funds

March 2, 2018 Medical Communications, Sales and Marketing Artificial Cell Technologies, cfo, pharma

A high-ranking C-level executive of a US biotech start-up has been charged with embezzling almost $1 million from the company …
News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026